Croom Medical

PlatformCroom, Co. Limerick, IrelandFounded 1984· One of 212 Platform companies tracked by AMPulse

Croom Medical specializes in precision manufacturing for orthopedic implants and medical devices, utilizing advanced additive manufacturing solutions including 3D printing technology.

CEO / Founder: Patrick Byrnes
Team Size: 51-200
Stage: Active
Total Funding: $29.7M
Key Investors: BGF, Enterprise Ireland

Technology & Products

Key Products

Croom Medical specializes in precision manufacturing for orthopedic implants and medical devices, utilizing advanced additive manufacturing (3D printing) of Tantalum. Their portfolio includes the Biofuse 3D-printed porous ingrowth platform for orthopedic implants, as well as precision machining and product/process design services.

Technological Advantage

Over three decades of precision manufacturing expertise combined with advanced additive manufacturing capabilities.

Differentiation

Value Proposition

Delivers high-quality, precision-engineered orthopedic implants using advanced 3D printing of Tantalum, ensuring innovation, cost-effectiveness, and a sustainable supply chain.

How They Differentiate

Distinct expertise in 3D printing Tantalum, innovative platforms like TALOS, sustainable manufacturing practices, and rapid product development turnaround.

Market & Competition

Target Customers

Medical device manufacturers, orthopedic implant producers, and healthcare providers globally.

Industry Verticals

Medical Devices, Healthcare, Orthopedics, Industrial applications

Competitors

Stryker; Zimmer Biomet; DePuy Synthes; Other contract manufacturers in orthopedic implants

Growth & Milestones

Growth Metrics

Produces approximately 250,000 knee systems annually; manufactured over 60,000 devices using its 3D printing platform and over 20,000 additive implants as of September 2021

Major Milestones

Expected launch of the TALOS platform for 3D printed Tantalum solutions (targeted for 2025), Medtech Partner/Supplier of the Year Award, Development of a closed-loop sustainable supply chain for Tantalum powder in collaboration with GAM, Significant investment in additive manufacturing capabilities, ISO 9001 Certification (since 1990), First Global Supplier Award from Stryker Orthopedics (2007)

Notable Customers

Stryker; Howmedica Osteonics; Johnson & Johnson

https://croommedical.com

Recent coverage of Croom Medical

Why this company matters

AMPulse analysis, not a company disclosure

Croom Medical occupies a narrow but defensible niche: contract manufacturing of orthopedic implants using additively manufactured tantalum. While most metal AM in orthopedics relies on titanium or cobalt-chrome alloys, Croom has built its differentiation around tantalum, a refractory metal with superior biocompatibility and osseointegration properties. The company combines over three decades of precision machining experience with metal LPBF capabilities to serve medical device OEMs that demand both regulatory traceability and production scale.

The company's core platform is Biofuse, a 3D-printed porous ingrowth structure designed for orthopedic implants. Croom also offers full product and process design services alongside traditional precision machining. Its partnership with Global Advanced Metals (GAM) enables a closed-loop, sustainable supply chain for tantalum powder, addressing both cost and environmental concerns in medical-grade AM. The upcoming TALOS platform, expected in 2025, is positioned to further expand tantalum-based additive solutions.

Croom's customer base includes Stryker, Howmedica Osteonics, and Johnson & Johnson. The company produces roughly 250,000 knee systems annually and had manufactured over 60,000 devices using its 3D printing platform as of September 2021. Its ISO 9001 certification dates to 1990, and it received Stryker's first Global Supplier Award in 2007, indicating a long-standing relationship with a top-tier orthopedic OEM.

The primary competitive risk is that larger contract manufacturers or implant OEMs develop their own tantalum AM capabilities, eroding Croom's differentiation. However, the combination of tantalum process know-how, regulatory approvals, and a captive powder supply chain creates a meaningful barrier. With $29.7 million in funding from BGF and Enterprise Ireland, Croom has the capital to scale but remains a relatively small player in a market dominated by Zimmer Biomet and DePuy Synthes.